H., Nielsen, P
2017 Dec;26(4):23742
N Engl J Med 380:347357 Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK (2020) VERTIS CV Investigators
Beyond glycemic markers, the evaluation should include blood pressure at every visit, a fasting lipid panel annually, and assessment for nonalcoholic fatty liver disease (now termed metabolic dysfunction-associated steatotic liver disease, or MASLD) at diagnosis
10.3390/microorganisms13061211 43 KodaY.TerataniT.ChuP.-S.HagiharaY.MikamiY.HaradaY.et al (2021)